Cyanotech (CYAN) 10-K 27 Jun 23 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2023	Jun. 15, 2023	Sep. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000768408
Entity Registrant Name	Cyanotech Corp
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	0-14602
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	91-1206026
Entity Address, Address Line One	73-4460 Queen Kaahumanu Highway, Suite 102
Entity Address, City or Town	Kailua-Kona
Entity Address, State or Province	HI
Entity Address, Postal Zip Code	96740
City Area Code	808
Local Phone Number	326-1353
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	CYAN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 8,128,352.16
Entity Common Stock, Shares Outstanding		6,291,086
Auditor Name	GRANT THORNTON LLP
Auditor Firm ID	248
Auditor Location	Newport Beach, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash	$ 974,000	$ 2,589,000
Accounts receivable, net of allowance for doubtful accounts of $64 in 2023 and $67 in 2022	1,331,000	3,664,000
Inventories	10,707,000	9,466,000
Prepaid expenses and other current assets	484,000	545,000
Total current assets	13,496,000	16,264,000
Equipment and leasehold improvements, net	11,366,000	11,885,000
Operating lease right-of-use assets, net	4,776,000	3,787,000
Other assets	90,000	109,000
Total assets	29,728,000	32,045,000
Current liabilities:
Accounts payable	1,021,000	2,362,000
Accrued expenses	1,101,000	1,412,000
Customer deposits	89,000	164,000
Operating lease obligations, current portion	483,000	393,000
Line of credit	1,540,000	0
Line of credit – related party	500,000	0
Current maturities of long-term debt	3,369,000	490,000
Total current liabilities	8,103,000	4,821,000
Long-term debt, less current maturities	1,000,000	4,336,000
Long-term operating lease obligations	4,275,000	3,386,000
Other long-term liabilities	3,000	15,000
Total liabilities	13,381,000	12,558,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding	0	0
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 6,271,971 shares at March 31, 2023 and 6,202,223 shares at March 31, 2022	125,000	124,000
Additional paid-in capital	33,856,000	33,557,000
Accumulated deficit	(17,634,000)	(14,194,000)
Total stockholders’ equity	16,347,000	19,487,000
Total liabilities and stockholders’ equity	$ 29,728,000	$ 32,045,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Accounts receivable, allowance for doubtful accounts	$ 64	$ 67
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred, authorized shares (in shares)	10,000,000	10,000,000
Preferred, issued shares (in shares)	0	0
Preferred outstanding, shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.02	$ 0.02
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	6,271,971	6,202,223
Common stock, shares outstanding (in shares)	6,271,971	6,202,223

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Net sales	$ 23,178	$ 35,968	$ 32,345
Cost of sales	15,919	22,402	21,228
Gross profit	7,259	13,566	11,117
Operating expenses:
General and administrative	4,659	5,367	4,876
Sales and marketing	4,750	4,913	5,518
Research and development	770	712	639
Total operating expense	10,179	10,992	11,033
(Loss) income from operations	(2,920)	2,574	84
Other income (expense):
Interest expense, net	(502)	(392)	(550)
Gain on extinguishment of debt	0	0	1,389
Total other income (expense), net	(502)	(392)	839
(Loss) income before income taxes	(3,422)	2,182	923
Income tax expense	(18)	(28)	(3)
Net (loss) income	$ (3,440)	$ 2,154	$ 920
Net (loss) income per share:
Basic (in dollars per share)	$ (0.55)	$ 0.35	$ 0.15
Diluted (in dollars per share)	$ (0.55)	$ 0.35	$ 0.15
Shares used in calculation of net (loss) income per share:
Basic (in shares)	6,244	6,157	6,070
Diluted (in shares)	6,244	6,168	6,079

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Former Executive [Member] | Common Stock [Member]
Statement [Line Items]
Shares withheld from former executive for tax payments (in shares)			(3,635)
Shares withheld from former executive for tax payments			$ 0
Shares withheld for tax payments			0
Former Executive [Member] | Additional Paid-in Capital [Member]
Statement [Line Items]
Shares withheld from former executive for tax payments			0
Shares withheld for tax payments			0
Former Executive [Member] | Retained Earnings [Member]
Statement [Line Items]
Shares withheld from former executive for tax payments			0
Shares withheld for tax payments			0
Former Executive [Member]
Statement [Line Items]
Shares withheld from former executive for tax payments			0
Shares withheld for tax payments			$ 0
Common Stock [Member]
Statement [Line Items]
Balance (in shares)	6,202,223	6,116,073	6,011,885
Balance	$ 124	$ 122	$ 120
Issuances of common stock for Director Stock Grants (in shares)	64,489	55,438	66,395
Issuances of common stock for Director Stock Grants	$ 1	$ 1	$ 1
Issuance of common stock for exercise of stock options for cash (in shares)			19,000
Issuance of common stock for exercise of stock options for cash			$ 0
Issuance of common stock in connection with severance of former executive (in shares)			11,400
Issuance of common stock in connection with severance of former executive			$ 0
Shares withheld from former executive for tax payments (in shares)	(3,053)	(16,251)	(6,431)
Shares withheld from former executive for tax payments	$ 0	$ 0	$ 0
Issuance of vested shares of restricted stock (in shares)	8,312	46,963	17,469
Issuance of vested shares of restricted stock	$ 0	$ 1	$ 1
Share-based compensation expense	0	0	0
Net income (loss)	0	0	0
Shares withheld for tax payments	$ 0	$ 0	$ 0
Balance (in shares)	6,271,971	6,202,223	6,116,073
Balance	$ 125	$ 124	$ 122
Additional Paid-in Capital [Member]
Statement [Line Items]
Balance	33,557	33,267	32,994
Issuances of common stock for Director Stock Grants	157	157	157
Issuance of common stock for exercise of stock options for cash			68
Issuance of common stock in connection with severance of former executive			0
Shares withheld from former executive for tax payments	0	0	0
Issuance of vested shares of restricted stock	(10)	(53)	(8)
Share-based compensation expense	152	186	56
Net income (loss)	0	0	0
Shares withheld for tax payments	0	0	0
Balance	33,856	33,557	33,267
Retained Earnings [Member]
Statement [Line Items]
Balance	(14,194)	(16,348)	(17,268)
Issuances of common stock for Director Stock Grants	0	0	0
Issuance of common stock for exercise of stock options for cash			0
Issuance of common stock in connection with severance of former executive			0
Shares withheld from former executive for tax payments	0	0	0
Issuance of vested shares of restricted stock
Share-based compensation expense	0	0	0
Net income (loss)	(3,440)	2,154	920
Shares withheld for tax payments	0	0	0
Balance	(17,634)	(14,194)	(16,348)
Balance	19,487	17,041	15,846
Issuances of common stock for Director Stock Grants	158	158	$ 158
Issuance of common stock for exercise of stock options for cash (in shares)			19,000
Issuance of common stock for exercise of stock options for cash			$ 68
Issuance of common stock in connection with severance of former executive			0
Shares withheld from former executive for tax payments	0	0	0
Issuance of vested shares of restricted stock	(10)	(52)	(7)
Share-based compensation expense	152	186	56
Net income (loss)	(3,440)	2,154	920
Shares withheld for tax payments	0	0	0
Balance	$ 16,347	$ 19,487	$ 17,041

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (3,440,000)	$ 2,154,000	$ 920,000
Adjustments to reconcile net (loss) income to cash provided by (used in) operating activities:
Depreciation and amortization	1,655,000	1,599,000	1,748,000
Gain from extinguishment of debt – PPP loan	0	0	(1,389,000)
Loss on impairment of assets	5,000	21,000	64,000
Amortization of debt issue costs and other assets	40,000	57,000	90,000
Amortization of operating leases right-of-use assets	440,000	322,000	317,000
Share-based compensation expense	310,000	344,000	214,000
Provision for doubtful accounts	64,000	35,000	46,000
Net (increase) decrease in assets:
Accounts receivable	2,269,000	(1,263,000)	(328,000)
Inventories	(1,231,000)	(717,000)	1,238,000
Prepaid expenses and other assets	60,000	(74,000)	18,000
Net increase (decrease) in liabilities:
Accounts payable	(1,422,000)	(358,000)	4,000
Accrued expenses	(311,000)	568,000	3,000
Customer deposits	(75,000)	40,000	(203,000)
Operating lease obligations	(452,000)	(331,000)	(320,000)
Deferred rent and other liabilities	(12,000)	(18,000)	(22,000)
Net cash (used in) provided by operating activities	(2,100,000)	2,379,000	2,400,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment and leasehold improvements	(1,068,000)	(1,270,000)	(760,000)
Net cash used in investing activities	(1,068,000)	(1,270,000)	(760,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on short-term contract obligation	0	0	(38,000)
Net draws (payments) on line of credit	1,540,000	(1,000,000)	(1,000,000)
Net draws on line of credit – related party	500,000	0	0
Net (payments) draws on long-term debt – related party	0	(500,000)	0
Proceeds from long-term debt – PPP loan	0	0	1,381,000
Principal payments on long-term debt	(477,000)	(735,000)	(670,000)
Payments on finance leases	0	0	(24,000)
Taxes paid related to net share settlement of restricted stock units	(10,000)	(52,000)	(7,000)
Proceeds from issuance of common stock and exercise of stock options	0	0	68,000
Net cash provided by (used in) financing activities	1,553,000	(2,287,000)	(290,000)
Net (decrease) increase in cash	(1,615,000)	(1,178,000)	1,350,000
Cash at beginning of year	2,589,000	3,767,000	2,417,000
Cash at end of year	974,000	2,589,000	3,767,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	408,000	342,000	446,000
Income taxes	$ 32,000	$ 2,000	$ 14,000

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. ORGANIZATION AND BASIS OF PRESENTATION Cyanotech Corporation (the “Company”), located in Kailua-Kona, Hawaii, was incorporated in the state of Nevada on March 3, 1983 The Company is an agricultural company that produces high value natural products derived from microalgae grown in complex and intricate open-pond agricultural systems on the Kona coast of Hawaii. The Company's products include Hawaiian Spirulina Pacifica BioAstin Hawaiian Astaxanthin The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements include the accounts of Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. (“Nutrex Hawaii” or “Nutrex”). Intercompany balances and transactions have been eliminated in consolidation. Liquidity and Going Concern The accompanying consolidated financial statements, as of and for the fiscal year ended March 31, 2023, March 31, 2023. not March 31, 2023 not may As of March 31, 2023, March 31, 2022. March 31, 2023 2022, August 30, 2023, The Company also has a loan facility with a related party that allows the Company to borrow up to $1,000,000 on a revolving basis (the “Revolver”). At March 31, 2023 March 31, 2022, April 12, 2025 ( 5 15 As of March 31, 2023, August 2032. March 31, 2023, June 22, 2023, March 31, 2023, $1,770,000 June 21, 2023. March 31, 2022, In April 2019, April 12, 2021 December 14, 2022, 5 15 March 31, 2023 2022, April 12, 2025. The Company experienced a loss from operations resulting in net cash outflows from operating activities of $2,100,000 for the fiscal year ended March 31, 2023, 2023, Funds generated by operating activities and available cash are expected to continue to be the Company's most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. The Company has developed its operating plan to produce the cash flows necessary to meet all financial requirements through at least June 30, 2024. not no March 31, 2024.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported. Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions. Financial Instruments and Fair Value The Company applies a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 3 three Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; and ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified contractual term, the Level 2 Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value. Cash, Accounts Receivable, Accounts Payable, Accrued Expenses and Customer Deposits Line of Credit, Revolver and Long-Term Debt Cash Cash primarily consists of cash on hand and cash in bank deposits. Concentration Risk The Company maintains its cash accounts in banks located in Hawaii, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 March 31, 2023 2022 March 31, 2023, two March 31, 2022, two March 31, 2023 2022, Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not not 90 not Inventories Inventories are stated at the lower of cost or net realizable value. Inventories are determined using the first first third may The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, fixed production overhead costs, idle facilities, freight handling costs and spoilage, as an expense in the period incurred, without adjusting overhead absorption rates. Normal production capacity is defined as the production expected to be achieved over a number of periods or seasons under normal circumstances, taking into account the loss of capacity resulting from planned maintenance. Equipment and Leasehold Improvements Equipment and leasehold improvements are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives for equipment and furniture and fixtures, and the shorter of the land lease term (see Notes 4 7 Equipment 3 to 10 Furniture and fixtures 3 to 7 Leasehold improvements 10 to 25 Capital project costs are accumulated in construction-in-progress until completed, at which time the costs are transferred to the relevant asset and commence depreciation. Repairs and Maintenance costs are expensed in the period incurred. Repairs and maintenance that significantly increase the useful life or value of the asset are capitalized and depreciated over the remaining life of the asset. The Company capitalizes interest cost incurred on funds used to construct property and equipment. The capitalized interest is recorded as part of the asset to which it relates and is amortized over the asset’s estimated useful life. Impairment of Long-Lived Assets Management reviews long-lived assets, such as equipment, leasehold improvements and purchased intangibles subject to amortization for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not Accounting for Asset Retirement Obligations Management evaluates quarterly the potential liability for asset retirement obligations under the Company’s lease for its principal facility and corporate headquarters. No March 31, 2023 2022 7 Revenue Recognition The Company records revenue based on the five 1 2 3 4 5 may not Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 one Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the years ended March 31, 2023 2022, March 31, 2022 2021, one not Research and Development Research and development costs are expensed as incurred and consist primarily of labor, benefits and outside research. Advertising Advertising costs are expensed as incurred. Total advertising expense for the years ended March 31, 2023, 2022 2021 Income Taxes Income taxes are accounted for under the asset and liability method. The asset and liability method require the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using income tax rates applicable to the period in which the tax difference is expected to reverse. Judgment is required in determining any valuation allowance recorded against deferred tax assets, specifically net operating loss carryforwards, tax credit carryforwards and deductible temporary differences that may In evaluating a tax position for recognition, management evaluates whether it is more-likely-than- not not 50% March 31, 2023 2022, The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest expense in its consolidated statements of operations. During the years ended March 31, 2023 2022, Share-Based Compensation The Company accounts for share-based payment arrangements using fair value. The Company currently has no not The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company’s common stock over a period consistent with that of the expected term of the options. The expected term of the options is estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms. The forfeiture rate of the options is based on historical forfeitures of similar grants. Per Share Amounts Basic earnings (loss) per common share is calculated by dividing net income (loss) for the year by the weighted average number of common shares outstanding during the year. Diluted earnings per common share is calculated by dividing net income for the year by the sum of the weighted average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive securities”) that were outstanding during the year. Dilutive securities include restricted stock units and stock options granted pursuant to the Company’s stock option plans. Dilutive securities related to the Company’s stock option plans are included in the calculation of diluted earnings per common share using the treasury stock method. Potentially dilutive securities are excluded from the computation of earnings per share in periods in which a net loss is reported, as their effect would be antidilutive. A reconciliation of the numerators and denominators of the basic and diluted income (loss) per common share calculations for the years ended March 31, 2023, 2022 2021 11. Recent Accounting Pronouncements In December 2019, 2019 12, Simplifying the Accounting for Income Taxes 2019 12” 2019 12 December 15, 2020, April 1, 2021, no In June 2016, 2016 13, Financial Instruments - Credit Losses 326” November 2018 2018 19, Codification Improvements to Topic 326, December 15, 2022.

Note 3 - Inventories

Note 3 - Inventories	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. INVENTORIES Inventories consist of the following as of March 31, 2023 2022: 2023 2022 (in thousands) Raw materials $ 1,887 $ 1,490 Work in process 2,049 2,868 Finished goods 6,502 4,595 Supplies 269 513 Inventories $ 10,707 $ 9,466 The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, fixed production overhead costs, idle facilities, freight handling costs and spoilage, as an expense in the period incurred, without adjusting overhead absorption rates. Normal production capacity is defined as the production expected to be achieved over a number of periods or seasons under normal circumstances, taking into account the loss of capacity resulting from planned maintenance. The Company expensed abnormal production costs of $90,000, $0 and $110,000 to cost of sales for the fiscal years ended March 31, 2023, 2022 2021, Beginning in fiscal 2021, first six 2022 2023. not Other non-inventoriable fixed costs of $269,000, $136,000 and $179,000 were expensed to cost of sales for the fiscal years ended March 31, 2023, 2022 2021,

Note 4 - Equipment and Leasehol

Note 4 - Equipment and Leasehold Improvements	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. EQUIPMENT AND LEASEHOLD IMPROVEMENTS Equipment and leasehold improvements consist of the following as of March 31, 2023 2022: 2023 2022 (in thousands) Equipment $ 21,649 $ 20,231 Leasehold improvements 15,038 14,751 Furniture and fixtures 407 394 37,094 35,376 Less accumulated depreciation and amortization (25,947 ) (24,339 ) Construction in-progress 219 848 Equipment and leasehold improvements, net $ 11,366 $ 11,885 Management has determined that $5,000, $21,000 and $64,000 of asset impairment existed as of March 31, 2023, 2022 2021, Depreciation and amortization expense were approximately $1,655,000, $1,599,000 and $1,748,000 for the years ended March 31, 2023, 2022 2021,

Note 5 - Line of Credit and Lon

Note 5 - Line of Credit and Long-term Debt	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	5. LINE OF CREDIT AND LONG-TERM DEBT Total debt consists of the following at March 31, 2023 2022 2023 2022 (in thousands) Line of credit $ 1,540 $ — Line of credit – related party 500 — Long-term debt 3,369 3,938 Long-term debt – related party 1,000 1,000 Less current maturities (5,409 ) (490 ) Long-term debt, excluding current maturities 1,000 4,448 Less unamortized debt issuance costs — (112 ) Total long-term debt, net of current maturities and unamortized debt issuance costs $ 1,000 $ 4,336 Line of Credit and Term Loans On August 30, 2016, June 3, 2016, March 31, 2023 March 31, 2022) no At March 31, 2023 2022, March 31, 2023 August 30, 2022 August 30, 2023. The Credit Agreement grants the Bank the following security interests in the Company’s property: (a) a lien on the Company’s leasehold interest in its Kona facility; (b) an assignment of the Company’s interest in leases and rents on its Kona facility; and (c) a security interest in all fixtures, furnishings and equipment related to or used by the Company at the Kona facility. Each security interest is further subject to the terms of the Credit Agreement. In 2015, “2015 July 30, 2015 “2015 2015 $2,500,000, The provisions of the 2015 September 1, 2022. 2015 March 31, 2023 March 31, 2022) first no 2015 September 2022 March 31, 2022, In 2012, “2012 August 14, 2012 “2012 2012 2012 The provisions of the 2012 first August 14, 2032, nineteen 19 2012 March 31, 2023 March 31, 2022) first no 2012 March 31, 2023 2022, The 2015 one December 31 December 31, 2015. 2015 2012 one December 31 December 31, 2012. 2012 March 31, 2023 2022, March 31, 2023 Loan Covenants, Violations and Waiver The Company’s Credit Agreement, 2015 2012 March 31, 2023, not two June 22, 2023, March 31, 2023, June 21, 2023. March 31, 2022, Although the Term Loans mature in August 2032, twelve March 31, 2023. Long-term Debt PPP In response to the coronavirus ("COVID- 19" May 2020, May 2022. December 2020, 2021, Line of Credit and Debt Related Party In April 2019, April 2021. April 2021, April 2024, 15 December 2022, April 2025 March 31, 2023 2022, March 31, 2023 2022, March 31, 2023 2022, first no Future principal payments, excluding unamortized debt issuance costs, under the loans at March 31, 2023 Fiscal year ending March 31 (in thousands) 2024 $ 3,461 2026 1,000 Total principal payments $ 4,461

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. ACCRUED EXPENSES Accrued expenses as of March 31, 2023 2022 2023 2022 (in thousands) Bonus and profit sharing $ 143 $ 488 Wages 215 211 Vacation 393 392 Rent, interest and legal 30 108 Other accrued expenses 320 213 Total accrued expenses $ 1,101 $ 1,412

Note 7 - Operating Leases

Note 7 - Operating Leases	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. OPERATING LEASES The Company’s principal facility and its corporate headquarters are located at the Natural Energy Laboratory of Hawaii Authority (“NELHA”) at Keahole Point in Kailua-Kona, Hawaii. The Company leases two properties from the State of Hawaii under a 40-year commercial lease expiring in 2035 2037. not not The Company leases facilities, equipment and land under non-cancelable operating leases expiring through 2037. five January 1, 2023. March 31, 2023, 2022 2021 Right-of-use assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Right-of-use assets and liabilities were recognized at April 1, 2019 two two March 31, 2023, March 31, 2022, March 31, 2023, one Supplemental balance sheet information related to leases consist of the following as of: Operating leases Balance Sheet Classification March 31, 2023 March 31, 2022 (in thousands) Right-of-use assets Operating lease right-of-use assets $ 6,149 $ 4,720 Accumulated lease amortization Operating lease right-of-use assets (1,373 ) (933 ) Total right-of-use assets $ 4,776 $ 3,787 Current lease liabilities Operating lease obligations $ 483 $ 393 Non-current lease liabilities Long-term operating lease obligations 4,275 3,386 Total lease liabilities $ 4,758 $ 3,779 Maturities of lease liabilities at March 31, 2023 Fiscal year ending March 31 (in thousands) 2024 $ 810 2025 820 2026 797 2027 798 2028 683 Thereafter 2,760 Total undiscounted lease payments 6,668 Less: present value discount (1,910 ) Total lease liabilities balance $ 4,758 Rent expense, including contingent rent, under operating leases were $506,000, $713,000 and $616,000 for the years ended March 31, 2023, 2022 2021, March 31, 2023, 2022 2021,

Note 8 - Other Commitments and

Note 8 - Other Commitments and Contingencies	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. OTHER COMMITMENTS AND CONTINGENCIES From time to time, the Company may no March 31, 2023. As of March 31, 2023, 2022 2021, ten April 2026 not

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	9. SHARE-BASED COMPENSATION As of March 31, 2023, two 2016 “2016 2014 “2014 March 31, 2022, 2004 “2004 2004 On August 25, 2016, 2016 2016 March 31, 2023, 2016 On August 28, 2014, 2014 2014 2021 2014 March 31, 2023, 2014 The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans: As of March 31, 2023 Authorized Available Outstanding 2016 Plan 1,300,000 881,437 305,334 2014 Directors Plan 650,000 223,206 12,000 2004 Directors Plan — — 6,000 Total 1,950,000 1,104,643 323,334 Stock Options All stock option grants made under the equity-based compensation plans were issued at exercise prices no 2016 2004 2014 No ten 10 March 31, 2023, 2022 2021, A summary of option activity under the Company’s stock plans for the years ended March 31, 2023, 2022 2021 Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at March 31, 2020 318,300 $ 4.08 3.0 $ — Granted 130,000 2.35 Exercised (19,000 ) 3.59 Forfeited (55,000 ) 3.13 Outstanding at March 31, 2021 374,300 $ 3.64 3.9 $ 129,700 Granted 50,000 2.96 Forfeited (5,000 ) 5.21 Expired (166,800 ) 3.84 Outstanding at March 31, 2022 252,500 $ 3.34 6.5 $ 159,650 Granted 50,000 3.43 Expired (49,500 ) 5.80 Outstanding at March 31, 2023 253,000 $ 2.88 7.5 $ — Exercisable at March 31, 2023 111,333 $ 2.90 6.6 $ — The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company’s closing stock price of $0.88, $3.37 and $3.30 at March 31, 2023, 2022 2021, 2021 2023 2022. A summary of the Company’s non-vested options for the year ended March 31, 2023 Nonvested Options Shares Weighted Average Grant-Date Fair Value Nonvested at March 31, 2022 141,667 $ 1.33 Granted 50,000 1.94 Expired (50,000 ) 1.33 Nonvested at March 31, 2023 141,667 $ 1.55 The weighted average grant-date fair value of stock options granted during fiscal years 2023, 2022 2021 2023, 2022 2021 The following table summarizes the weighted average characteristics of outstanding stock options as of March 31, 2023: Outstanding Options Exercisable Options Range of Exercise Prices Number of Shares Remaining Life (Years) Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price $ 2.11 - $ 2.34 105,000 7.2 $ 2.28 55,000 $ 2.27 $ 2.35 - $2.76 30,000 7.5 $ 2.54 21,666 $ 2.53 $ 2.77 - $3.20 50,000 8.1 $ 2.96 16,667 $ 2.96 $ 3.21 - $5.91 68,000 7.3 $ 3.89 18,000 $ 5.18 Total stock options 253,000 7.5 $ 2.88 111,333 $ 2.90 The range of fair value assumptions related to options granted during the years ended March 31, 2023, 2022 2021 2023 2022 2021 Exercise Price $ 1.94 $ 1.60 $ 1.20 Volatility 57.47 % 58.23 % 54.44 % Risk Free Rate 3.36 % 1.06 % 0.40 % Vesting Period (in years) 3.0 3.0 3.0 Forfeiture Rate 19 % 0 % 0 % Expected Life (in years) 6.0 6.0 6.2 Dividend Rate 0 % 0 % 0 % Total unrecognized stock-based compensation expense related to all unvested stock options was $124,000 and $139,000, at March 31, 2023 2022, Restricted Stock Grants of fully vested restricted stock issued to Non-Employee Directors during fiscal years 2023, 2022 2021 2014 March 31, 2023, 2022 2021, To reduce the Company’s ongoing cash expenses, the Nominating and Corporate Governance Committee of the Board of Directors adopted a resolution allowing each director to elect to receive his or her quarterly director fees in the form of restricted stock in lieu of cash. Two Board members elected to receive shares of restricted stock in lieu of cash for the third 2023. April 3, 2023, two March 31, 2023, Restricted Stock Units ( RSUs ) RSUs are service-based awards granted to eligible employees under our 2016 2016 March 31, 2023, 2022 2021, The following table summarizes information related to awarded RSUs: Nonvested Restricted Stock Units Shares Weighted Average Grant Price Nonvested restricted stock units at March 31, 2020 12,766 $ 3.98 Granted 28,647 $ 2.15 Vested (9,135 ) $ 3.97 Forfeited (4,090 ) $ 2.21 Nonvested restricted stock units at March 31, 2021 28,188 $ 2.38 Granted 38,672 $ 2.91 Vested (46,963 ) $ 2.85 Forfeited (5,432 ) $ 2.51 Nonvested restricted stock units at March 31, 2022 14,465 $ 2.22 Granted 66,423 $ 3.13 Vested (8,312 ) $ 2.35 Forfeited (2,242 ) $ 2.91 Nonvested restricted stock units at March 31, 2023 70,334 $ 3.04 Total unrecognized stock-based compensation expense related to unvested restricted stock units was $122,000 and $19,000 at March 31, 2023 2022, On April 6, 2023, three

Note 10 - Common and Preferred

Note 10 - Common and Preferred Stock	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	10. COMMON AND PREFERRED STOCK The Company has authorized a total of sixty million shares of which fifty million shares are authorized common stock and ten million shares are authorized preferred stock. None of the preferred stock was issued or outstanding at March 31, 2023 2022.

Note 11 - Earnings (Loss) Per S

Note 11 - Earnings (Loss) Per Share	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	11. EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding. Diluted earnings per share is computed on the basis of the weighted average number of common shares outstanding plus the potentially dilutive effect of outstanding stock options and unvested restricted stock units using the treasury stock method. Reconciliations between the numerator and the denominator of the basic and diluted income (loss) per share computations for the years ended March 31, 2023, 2022 2021 Net Income (loss) (Numerator) Shares (Denominator) Per Share Amount (in thousands, except per share amounts) Year ended March 31, 2023: Basic and diluted loss per share $ (3,440 ) 6,244 $ (0.55 ) Year ended March 31, 2022: Basic income per share $ 2,154 6,157 $ 0.35 Effective dilutive securities—Common stock options and restricted stock units — 11 — Diluted income per share $ 2,154 6,168 $ 0.35 Year ended March 31, 2021: Basic income per share $ 920 6,070 $ 0.15 Effective dilutive securities—Common stock options and restricted stock units — 8 — Diluted income per share $ 920 6,079 $ 0.15 Basic and diluted per share amounts are the same in periods of a net loss because common share equivalents are anti-dilutive when a net loss is recorded. Diluted earnings per share does not March 31, 2023,

Note 12 - Profit Sharing and 40

Note 12 - Profit Sharing and 401k Plan	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Profit Sharing Plan and 401 Plan Disclosure [Text Block]	12. PROFIT SHARING AND 401 The Company sponsors a profit sharing plan for all employees not may may 401 may 401 March 31, 2023, 2022 2021, 401 two March 31, 2023, 2022 2021,

Note 13 - Product Line and Geog

Note 13 - Product Line and Geographic Information	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	13. PRODUCT LINE AND GEOGRAPHIC INFORMATION Disaggregation of Revenue The following table represents revenue disaggregated by major product line and extraction services for the years ended March 31, 2023, 2022 2021 2023 2022 2021 Packaged sales Astaxanthin packaged $ 12,227 $ 14,931 $ 14,512 Spirulina packaged 4,814 7,604 7,616 Total packaged sales 17,041 22,535 22,128 Bulk sales Astaxanthin bulk 1,982 2,447 2,279 Spirulina bulk 3,541 10,386 7,119 Total bulk sales 5,523 12,833 9,398 Contract extraction and R&D services revenue 614 600 819 Total net sales $ 23,178 $ 35,968 $ 32,345 Cost of sales for contract extraction and R&D services for the years ended March 31, 2023, 2022 2021 Net sales by geographic region for the years ended March 31, 2023, 2022 2021 2023 2022 2021 (dollars in thousands) Net sales(1): United States $ 17,031 73 % $ 24,468 68 % $ 21,474 66 % Asia / Pacific 2,164 9 % 7,102 20 % 5,827 18 % Europe 2,440 11 % 3,183 9 % 3,416 11 % Other 1,543 7 % 1,215 3 % 1,628 5 % $ 23,178 100 % $ 35,968 100 % $ 32,345 100 % ( 1 Net sales are attributed to countries based on location of customer.

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. INCOME TAXES On December 22, 2017, 1, January 1, 2022, 174 five 15 The Inflation Reduction Act of 2022 August 16, 2022. three 1% not 2023. On August 9, 2022, 2022 not 2023. Income tax (expense) benefit for the years ended March 31, 2023, 2022 2021 2023 2022 2021 (in thousands) Current: Federal $ — $ — $ — State (18 ) (28 ) (3 ) Total current (expense) benefit (18 ) (28 ) (3 ) Deferred: Federal — — — State — — — Total deferred expense — — — Income tax expense $ (18 ) $ (28 ) $ (3 ) The following table reconciles the amount of income taxes computed at the federal tax rate of 21% for each of the years ended March 31, 2023, 2022 2021, March 31, 2023, 2022 2021: 2023 2022 2021 (in thousands) Tax provision at federal statutory income tax rate $ 952 $ (591 ) $ (263 ) Stock-based compensation (23 ) (16 ) (11 ) Decrease (increase) in valuation allowance (518 ) 557 (17 ) State and local income taxes, net of federal tax benefit (12 ) (2 ) 1 Expired losses (380 ) — — Deferred tax true-up (24 ) 34 27 CARES Act, PPP Loan Forgiveness — — 298 Other, net (13 ) (10 ) (38 ) Income tax expense $ (18 ) $ (28 ) $ (3 ) The tax effects of temporary differences related to various assets, liabilities and carry forwards that give rise to deferred tax assets and deferred tax liabilities as of March 31, 2023 2022 2023 2022 (in thousands) Deferred tax assets: Net operating loss carry forwards $ 3,570 $ 3,140 Inventory 50 175 Compensation accrual 177 251 Tax credit carry forwards 28 28 Interest limitation 108 — Operating lease right-of-use assets 1,323 1,025 Section 174 Costs 118 — Other 26 27 Gross deferred tax assets 5,400 4,646 Less valuation allowance (2,990 ) (2,473 ) Net deferred tax assets 2,410 2,173 Deferred tax liabilities: Operating lease obligations (1,328 ) (1,027 ) Depreciation and amortization (1,082 ) (1,146 ) Net deferred tax liabilities (2,410 ) (2,173 ) Net deferred tax assets (liabilities) $ — $ — In assessing the valuation allowance for deferred tax assets, management considers whether it is more likely than not not As of March 31, 2023, 2022 2021, While the Company’s long-term financial outlook remains positive, the Company concluded that its ability to rely on its long-term outlook as to future taxable income was limited due to the relative weight of the negative evidence from its recent cumulative losses. The Company’s conclusion regarding the need for a valuation allowance against its deferred tax assets could change in the future based on improvements in operating performance, which may At March 31, 2023, Expires March 31, Net Operating Loss State Net Operating Losses Research and Experimentation Tax Credit (in thousands) 2025 $ — $ — $ 8 2026 159 — 2 2027 2,665 — — Thereafter 4,379 11,150 18 Indefinite 6,850 — — $ 14,053 $ 11,150 $ 28 At March 31, 2023, 2018 100% 2018 80% March 31, 2023, March 31, 2030 2040. March 31, 2023, March 31, 2030 2040. March 31, 2023, The following, in general, represents the open tax years and jurisdictions that the Company used in its evaluation of tax positions. The Company has unused net operating losses carried forward, which cause the statute to remain open up to the amount of unused loss with the statute not Open tax years ending March 31, Jurisdiction 2020 - 2023 U.S. Federal 2020 - 2023 State of Hawaii 2019 - 2023 State of California

Note 15 - Related Party Transac

Note 15 - Related Party Transactions and Balances	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	15. RELATED-PARTY TRANSACTIONS AND BALANCES In April 2019, April 12, 2021. On April 12, 2021, may not $500,000, three April 12, 2021, no may On April 12, 2021, two On December 14, 2022, April 12, 2025 may At both March 31, 2023 2022, $1,000,000, March 31, 2023 2022, March 31, 2023 2022,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	16. SUBSEQUENT EVENTS On May 2, 2023, not 5550 2 $1.00 30 no 180 October 30, 2023, $1.00 ten 180 On June 15, 2023, 5500 2 The Company had no 6 June 22, 2023, 9 April 2023.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	II Cyanotech Corporation Valuation and Qualifying Accounts Years Ended March 31, 2023, 2022 2021 (in thousands) Additions Description Balance at Beginning of Year Charged to Costs and Expense Charged to Other Accounts Deductions Balance at End of Year Allowance for Doubtful Accounts: 2023 $ 67 $ 64 $ — $ 67 $ 64 2022 32 40 — 5 67 2021 13 46 — 27 32

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported. Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments and Fair Value The Company applies a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 3 three Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; and ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified contractual term, the Level 2 Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value. Cash, Accounts Receivable, Accounts Payable, Accrued Expenses and Customer Deposits Line of Credit, Revolver and Long-Term Debt
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Cash primarily consists of cash on hand and cash in bank deposits.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Risk The Company maintains its cash accounts in banks located in Hawaii, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 March 31, 2023 2022 March 31, 2023, two March 31, 2022, two March 31, 2023 2022,
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not not 90 not
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value. Inventories are determined using the first first third may The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, fixed production overhead costs, idle facilities, freight handling costs and spoilage, as an expense in the period incurred, without adjusting overhead absorption rates. Normal production capacity is defined as the production expected to be achieved over a number of periods or seasons under normal circumstances, taking into account the loss of capacity resulting from planned maintenance.
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment and Leasehold Improvements Equipment and leasehold improvements are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives for equipment and furniture and fixtures, and the shorter of the land lease term (see Notes 4 7 Equipment 3 to 10 Furniture and fixtures 3 to 7 Leasehold improvements 10 to 25 Capital project costs are accumulated in construction-in-progress until completed, at which time the costs are transferred to the relevant asset and commence depreciation. Repairs and Maintenance costs are expensed in the period incurred. Repairs and maintenance that significantly increase the useful life or value of the asset are capitalized and depreciated over the remaining life of the asset. The Company capitalizes interest cost incurred on funds used to construct property and equipment. The capitalized interest is recorded as part of the asset to which it relates and is amortized over the asset’s estimated useful life.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Management reviews long-lived assets, such as equipment, leasehold improvements and purchased intangibles subject to amortization for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not
Asset Retirement Obligation [Policy Text Block]	Accounting for Asset Retirement Obligations Management evaluates quarterly the potential liability for asset retirement obligations under the Company’s lease for its principal facility and corporate headquarters. No March 31, 2023 2022 7
Revenue [Policy Text Block]	Revenue Recognition The Company records revenue based on the five 1 2 3 4 5 may not Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 one Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the years ended March 31, 2023 2022, March 31, 2022 2021, one not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred and consist primarily of labor, benefits and outside research.
Advertising Cost [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Total advertising expense for the years ended March 31, 2023, 2022 2021
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. The asset and liability method require the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using income tax rates applicable to the period in which the tax difference is expected to reverse. Judgment is required in determining any valuation allowance recorded against deferred tax assets, specifically net operating loss carryforwards, tax credit carryforwards and deductible temporary differences that may In evaluating a tax position for recognition, management evaluates whether it is more-likely-than- not not 50% March 31, 2023 2022, The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest expense in its consolidated statements of operations. During the years ended March 31, 2023 2022,
Share-Based Payment Arrangement [Policy Text Block]	Share-Based Compensation The Company accounts for share-based payment arrangements using fair value. The Company currently has no not The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company’s common stock over a period consistent with that of the expected term of the options. The expected term of the options is estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms. The forfeiture rate of the options is based on historical forfeitures of similar grants.
Earnings Per Share, Policy [Policy Text Block]	Per Share Amounts Basic earnings (loss) per common share is calculated by dividing net income (loss) for the year by the weighted average number of common shares outstanding during the year. Diluted earnings per common share is calculated by dividing net income for the year by the sum of the weighted average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive securities”) that were outstanding during the year. Dilutive securities include restricted stock units and stock options granted pursuant to the Company’s stock option plans. Dilutive securities related to the Company’s stock option plans are included in the calculation of diluted earnings per common share using the treasury stock method. Potentially dilutive securities are excluded from the computation of earnings per share in periods in which a net loss is reported, as their effect would be antidilutive. A reconciliation of the numerators and denominators of the basic and diluted income (loss) per common share calculations for the years ended March 31, 2023, 2022 2021 11.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In December 2019, 2019 12, Simplifying the Accounting for Income Taxes 2019 12” 2019 12 December 15, 2020, April 1, 2021, no In June 2016, 2016 13, Financial Instruments - Credit Losses 326” November 2018 2018 19, Codification Improvements to Topic 326, December 15, 2022.

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Property, Plant, and Equipment, Estimated Useful Lives [Table Text Block]	Equipment 3 to 10 Furniture and fixtures 3 to 7 Leasehold improvements 10 to 25

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	2023 2022 (in thousands) Raw materials $ 1,887 $ 1,490 Work in process 2,049 2,868 Finished goods 6,502 4,595 Supplies 269 513 Inventories $ 10,707 $ 9,466

Note 4 - Equipment and Leaseh_2

Note 4 - Equipment and Leasehold Improvements (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	2023 2022 (in thousands) Equipment $ 21,649 $ 20,231 Leasehold improvements 15,038 14,751 Furniture and fixtures 407 394 37,094 35,376 Less accumulated depreciation and amortization (25,947 ) (24,339 ) Construction in-progress 219 848 Equipment and leasehold improvements, net $ 11,366 $ 11,885

Note 5 - Line of Credit and L_2

Note 5 - Line of Credit and Long-term Debt (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	2023 2022 (in thousands) Line of credit $ 1,540 $ — Line of credit – related party 500 — Long-term debt 3,369 3,938 Long-term debt – related party 1,000 1,000 Less current maturities (5,409 ) (490 ) Long-term debt, excluding current maturities 1,000 4,448 Less unamortized debt issuance costs — (112 ) Total long-term debt, net of current maturities and unamortized debt issuance costs $ 1,000 $ 4,336
Schedule of Maturities of Long-Term Debt [Table Text Block]	Fiscal year ending March 31 (in thousands) 2024 $ 3,461 2026 1,000 Total principal payments $ 4,461

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2023 2022 (in thousands) Bonus and profit sharing $ 143 $ 488 Wages 215 211 Vacation 393 392 Rent, interest and legal 30 108 Other accrued expenses 320 213 Total accrued expenses $ 1,101 $ 1,412

Note 7 - Operating Leases (Tabl

Note 7 - Operating Leases (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Supplement Balance Sheet Information for Operating Lease [Table Text Block]	Operating leases Balance Sheet Classification March 31, 2023 March 31, 2022 (in thousands) Right-of-use assets Operating lease right-of-use assets $ 6,149 $ 4,720 Accumulated lease amortization Operating lease right-of-use assets (1,373 ) (933 ) Total right-of-use assets $ 4,776 $ 3,787 Current lease liabilities Operating lease obligations $ 483 $ 393 Non-current lease liabilities Long-term operating lease obligations 4,275 3,386 Total lease liabilities $ 4,758 $ 3,779
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Fiscal year ending March 31 (in thousands) 2024 $ 810 2025 820 2026 797 2027 798 2028 683 Thereafter 2,760 Total undiscounted lease payments 6,668 Less: present value discount (1,910 ) Total lease liabilities balance $ 4,758

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Share-based Compensation Shares Authorized Available and Outstanding by Plan [Table Text Block]	As of March 31, 2023 Authorized Available Outstanding 2016 Plan 1,300,000 881,437 305,334 2014 Directors Plan 650,000 223,206 12,000 2004 Directors Plan — — 6,000 Total 1,950,000 1,104,643 323,334
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at March 31, 2020 318,300 $ 4.08 3.0 $ — Granted 130,000 2.35 Exercised (19,000 ) 3.59 Forfeited (55,000 ) 3.13 Outstanding at March 31, 2021 374,300 $ 3.64 3.9 $ 129,700 Granted 50,000 2.96 Forfeited (5,000 ) 5.21 Expired (166,800 ) 3.84 Outstanding at March 31, 2022 252,500 $ 3.34 6.5 $ 159,650 Granted 50,000 3.43 Expired (49,500 ) 5.80 Outstanding at March 31, 2023 253,000 $ 2.88 7.5 $ — Exercisable at March 31, 2023 111,333 $ 2.90 6.6 $ —
Schedule of Nonvested Share Activity [Table Text Block]	Nonvested Options Shares Weighted Average Grant-Date Fair Value Nonvested at March 31, 2022 141,667 $ 1.33 Granted 50,000 1.94 Expired (50,000 ) 1.33 Nonvested at March 31, 2023 141,667 $ 1.55
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding Options Exercisable Options Range of Exercise Prices Number of Shares Remaining Life (Years) Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price $ 2.11 - $ 2.34 105,000 7.2 $ 2.28 55,000 $ 2.27 $ 2.35 - $2.76 30,000 7.5 $ 2.54 21,666 $ 2.53 $ 2.77 - $3.20 50,000 8.1 $ 2.96 16,667 $ 2.96 $ 3.21 - $5.91 68,000 7.3 $ 3.89 18,000 $ 5.18 Total stock options 253,000 7.5 $ 2.88 111,333 $ 2.90
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2023 2022 2021 Exercise Price $ 1.94 $ 1.60 $ 1.20 Volatility 57.47 % 58.23 % 54.44 % Risk Free Rate 3.36 % 1.06 % 0.40 % Vesting Period (in years) 3.0 3.0 3.0 Forfeiture Rate 19 % 0 % 0 % Expected Life (in years) 6.0 6.0 6.2 Dividend Rate 0 % 0 % 0 %
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nonvested Restricted Stock Units Shares Weighted Average Grant Price Nonvested restricted stock units at March 31, 2020 12,766 $ 3.98 Granted 28,647 $ 2.15 Vested (9,135 ) $ 3.97 Forfeited (4,090 ) $ 2.21 Nonvested restricted stock units at March 31, 2021 28,188 $ 2.38 Granted 38,672 $ 2.91 Vested (46,963 ) $ 2.85 Forfeited (5,432 ) $ 2.51 Nonvested restricted stock units at March 31, 2022 14,465 $ 2.22 Granted 66,423 $ 3.13 Vested (8,312 ) $ 2.35 Forfeited (2,242 ) $ 2.91 Nonvested restricted stock units at March 31, 2023 70,334 $ 3.04

Note 11 - Earnings (Loss) Per_2

Note 11 - Earnings (Loss) Per Share (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Net Income (loss) (Numerator) Shares (Denominator) Per Share Amount (in thousands, except per share amounts) Year ended March 31, 2023: Basic and diluted loss per share $ (3,440 ) 6,244 $ (0.55 ) Year ended March 31, 2022: Basic income per share $ 2,154 6,157 $ 0.35 Effective dilutive securities—Common stock options and restricted stock units — 11 — Diluted income per share $ 2,154 6,168 $ 0.35 Year ended March 31, 2021: Basic income per share $ 920 6,070 $ 0.15 Effective dilutive securities—Common stock options and restricted stock units — 8 — Diluted income per share $ 920 6,079 $ 0.15

Note 13 - Product Line and Ge_2

Note 13 - Product Line and Geographic Information (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	2023 2022 2021 Packaged sales Astaxanthin packaged $ 12,227 $ 14,931 $ 14,512 Spirulina packaged 4,814 7,604 7,616 Total packaged sales 17,041 22,535 22,128 Bulk sales Astaxanthin bulk 1,982 2,447 2,279 Spirulina bulk 3,541 10,386 7,119 Total bulk sales 5,523 12,833 9,398 Contract extraction and R&D services revenue 614 600 819 Total net sales $ 23,178 $ 35,968 $ 32,345
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	2023 2022 2021 (dollars in thousands) Net sales(1): United States $ 17,031 73 % $ 24,468 68 % $ 21,474 66 % Asia / Pacific 2,164 9 % 7,102 20 % 5,827 18 % Europe 2,440 11 % 3,183 9 % 3,416 11 % Other 1,543 7 % 1,215 3 % 1,628 5 % $ 23,178 100 % $ 35,968 100 % $ 32,345 100 %

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2023 2022 2021 (in thousands) Current: Federal $ — $ — $ — State (18 ) (28 ) (3 ) Total current (expense) benefit (18 ) (28 ) (3 ) Deferred: Federal — — — State — — — Total deferred expense — — — Income tax expense $ (18 ) $ (28 ) $ (3 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2023 2022 2021 (in thousands) Tax provision at federal statutory income tax rate $ 952 $ (591 ) $ (263 ) Stock-based compensation (23 ) (16 ) (11 ) Decrease (increase) in valuation allowance (518 ) 557 (17 ) State and local income taxes, net of federal tax benefit (12 ) (2 ) 1 Expired losses (380 ) — — Deferred tax true-up (24 ) 34 27 CARES Act, PPP Loan Forgiveness — — 298 Other, net (13 ) (10 ) (38 ) Income tax expense $ (18 ) $ (28 ) $ (3 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2023 2022 (in thousands) Deferred tax assets: Net operating loss carry forwards $ 3,570 $ 3,140 Inventory 50 175 Compensation accrual 177 251 Tax credit carry forwards 28 28 Interest limitation 108 — Operating lease right-of-use assets 1,323 1,025 Section 174 Costs 118 — Other 26 27 Gross deferred tax assets 5,400 4,646 Less valuation allowance (2,990 ) (2,473 ) Net deferred tax assets 2,410 2,173 Deferred tax liabilities: Operating lease obligations (1,328 ) (1,027 ) Depreciation and amortization (1,082 ) (1,146 ) Net deferred tax liabilities (2,410 ) (2,173 ) Net deferred tax assets (liabilities) $ — $ —
Schedule of Operating Loss and Tax Credit Carry Forwards [Table Text Block]	Expires March 31, Net Operating Loss State Net Operating Losses Research and Experimentation Tax Credit (in thousands) 2025 $ — $ — $ 8 2026 159 — 2 2027 2,665 — — Thereafter 4,379 11,150 18 Indefinite 6,850 — — $ 14,053 $ 11,150 $ 28
Summary of Income Tax Contingencies [Table Text Block]	Open tax years ending March 31, Jurisdiction 2020 - 2023 U.S. Federal 2020 - 2023 State of Hawaii 2019 - 2023 State of California

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Valuation Allowances and Reserves [Table Text Block]	Additions Description Balance at Beginning of Year Charged to Costs and Expense Charged to Other Accounts Deductions Balance at End of Year Allowance for Doubtful Accounts: 2023 $ 67 $ 64 $ — $ 67 $ 64 2022 32 40 — 5 67 2021 13 46 — 27 32

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Jun. 21, 2023	Dec. 31, 2022	Apr. 30, 2019	Aug. 30, 2016
Statement [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 974,000	$ 2,589,000
Working Capital (Deficit)	5,393,000	11,443,000
Line of Credit, Current	1,540,000	0
Lines of Credit, Related Party, Current	500,000	0
Long-term Debt and Capital Lease Obligations, Current and Noncurrent	3,461,000
Net Cash Provided by (Used in) Operating Activities	(2,100,000)	2,379,000	$ 2,400,000
Proceeds from Lines of Credit, Related Parties	500,000	0	$ 0
Term Loan Agreement, Maturing on August 14, 2032 [Member]
Statement [Line Items]
Long-term Debt and Capital Lease Obligations, Current and Noncurrent	3,461,000	3,720,000
Unsecured Subordinated Loan From Skywords [Member]
Statement [Line Items]
Debt Instrument, Face Amount	1,000,000	1,000,000				$ 1,500,000
Subsequent Event [Member] | Term Loan Agreement, Maturing on August 14, 2032 [Member]
Statement [Line Items]
Debt Covenant, Further Advances of Credit Agreement, Immediate Freeze				$ 1,770,000
First Foundation Bank [Member]
Statement [Line Items]
Proceeds from Lines of Credit	1,540,000
First Foundation Bank [Member] | Revolving Credit Facility [Member]
Statement [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	2,000,000						$ 2,000,000
Line of Credit, Current	1,540,000	0
Related Party 1 [Member] | Revolving Credit Facility [Member]
Statement [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	1,000,000				$ 1,000,000
Lines of Credit, Related Party, Current	500,000	$ 0
Proceeds from Lines of Credit, Related Parties	$ 500,000

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual)	12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Statement [Line Items]
Cash, Uninsured Amount	$ 422,000	$ 2,089,000
Contract with Customer, Liability, Revenue Recognized	94,000	55,000
Advertising Expense	1,513,000	1,458,000	$ 2,116,000
Unrecognized Tax Benefits	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 0	$ 0
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Statement [Line Items]
Number of Major Customers	2	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Number 1 [Member]
Statement [Line Items]
Concentration Risk, Percentage	34%	22%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Number 2 [Member]
Statement [Line Items]
Concentration Risk, Percentage	6%	19%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Statement [Line Items]
Number of Major Customers	2	2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Statement [Line Items]
Concentration Risk, Percentage	46%	63%

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Estimated Useful Lives (Details)	Mar. 31, 2023
Equipment [Member] | Minimum [Member]
Statement [Line Items]
Estimated useful lives (Year)	3 years
Equipment [Member] | Maximum [Member]
Statement [Line Items]
Estimated useful lives (Year)	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Statement [Line Items]
Estimated useful lives (Year)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Statement [Line Items]
Estimated useful lives (Year)	7 years
Leasehold Improvements [Member] | Minimum [Member]
Statement [Line Items]
Estimated useful lives (Year)	10 years
Leasehold Improvements [Member] | Maximum [Member]
Statement [Line Items]
Estimated useful lives (Year)	25 years

Note 3 - Inventories (Details T

Note 3 - Inventories (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Inventory Abnormal Production Costs	$ 90,000	$ 0	$ 110,000
Non Inventoriable Fixed Costs	$ 269,000	$ 136,000	$ 179,000

Note 3 - Inventories - Componen

Note 3 - Inventories - Components of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Raw materials	$ 1,887	$ 1,490
Work in process	2,049	2,868
Finished goods	6,502	4,595
Supplies	269	513
Inventories	$ 10,707	$ 9,466

Note 4 - Equipment and Leaseh_3

Note 4 - Equipment and Leasehold Improvements (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Asset Impairment Charges	$ 5,000	$ 21,000	$ 64,000
Depreciation, Depletion and Amortization	$ 1,655,000	$ 1,599,000	$ 1,748,000

Note 4 - Equipment and Leaseh_4

Note 4 - Equipment and Leasehold Improvements - Components of Equipment and Leasehold Improvements (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Equipment and leasehold improvements, gross	$ 37,094	$ 35,376
Less accumulated depreciation and amortization	(25,947)	(24,339)
Construction in-progress	219	848
Equipment and leasehold improvements, net	11,366	11,885
Equipment [Member]
Statement [Line Items]
Equipment and leasehold improvements, gross	21,649	20,231
Leasehold Improvements [Member]
Statement [Line Items]
Equipment and leasehold improvements, gross	15,038	14,751
Furniture and Fixtures [Member]
Statement [Line Items]
Equipment and leasehold improvements, gross	$ 407	$ 394

Note 5 - Line of Credit and L_3

Note 5 - Line of Credit and Long-term Debt (Details Textual) - USD ($)					1 Months Ended		12 Months Ended
	Apr. 12, 2021	Aug. 30, 2016	Jul. 30, 2015	Aug. 14, 2012	Apr. 30, 2021	May 31, 2020	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Jun. 21, 2023	Dec. 31, 2022	Dec. 14, 2022	Apr. 30, 2019
Statement [Line Items]
Line of Credit, Current							$ 1,540,000	$ 0
Long-term Debt and Capital Lease Obligations, Current and Noncurrent							3,461,000
Debt Issuance Costs, Current, Net							92,000
Debt Issuance Costs, Net							0	112,000
Proceeds from Issuance of Unsecured Debt							0	0	$ 1,381,000
Gain (Loss) on Extinguishment of Debt							0	0	1,389,000
Long-term Debt, Current Maturities, Total							5,409,000	490,000
Interest Paid, Excluding Capitalized Interest, Operating Activities							408,000	342,000	446,000
Lines of Credit, Related Party, Current							500,000	0
Unsecured Subordinated Loan [Member]
Statement [Line Items]
Long-Term Debt, Gross							1,000,000	1,000,000
The 2015 Loan Agreement [Member]
Statement [Line Items]
Proceeds from Issuance of Debt			$ 2,500,000
Long-term Debt and Capital Lease Obligations, Current and Noncurrent								$ 218,000
Debt Instrument One Time Origination and Guaranty Fees							$ 113,900
Debt Instrument Annual Renewal Fee Payable Percentage							0.50%
Debt Instrument Guaranteed Portion							80%
The 2015 Loan Agreement [Member] | Minimum [Member]
Statement [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			6%
Term Loan Agreement, Maturing on August 14, 2032 [Member]
Statement [Line Items]
Debt Instrument Reference Rate							7.50%	3.25%
Debt Instrument, Basis Spread on Variable Rate				1%
Proceeds from Issuance of Debt				$ 5,500,000
Long-term Debt and Capital Lease Obligations, Current and Noncurrent							$ 3,461,000	$ 3,720,000
Debt Instrument Interest Payment Period (Month)				12 months
Debt Instrument Amortization Period (Year)				19 years
Debt Instrument One Time Origination and Guaranty Fees							$ 214,500
Debt Instrument Annual Renewal Fee Payable Percentage							0.25%
Debt Instrument Guaranteed Portion							80%
Term Loan Agreement, Maturing on August 14, 2032 [Member] | Subsequent Event [Member]
Statement [Line Items]
Debt Covenant, Further Advances of Credit Agreement, Immediate Freeze											$ 1,770,000
Term Loan Agreement, Maturing on August 14, 2032 [Member] | Minimum [Member]
Statement [Line Items]
Debt Instrument, Interest Rate During Period				5.50%
Term Loan Agreement, Promissory Note One [Member]
Statement [Line Items]
Proceeds from Issuance of Debt				$ 2,250,000
Term Loan Agreement, Promissory Note Two [Member]
Statement [Line Items]
Proceeds from Issuance of Debt				$ 3,250,000
SBA CARES Act Paycheck Protection Program [Member]
Statement [Line Items]
Proceeds from Issuance of Unsecured Debt						$ 1,381,000
Debt Instrument, Decrease, Principal Forgiveness									1,381,000
Debt Instrument, Decrease, Accrued Interest Forgiveness									8,000
Gain (Loss) on Extinguishment of Debt									$ 1,389,000
Skywords Note [Member]
Statement [Line Items]
Debt Instrument Reference Rate							7.50%	3.25%
Repayments of Long-term Debt, Total	$ 500,000				$ 500,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	1,900				1,900
Skywords Note [Member] | Unsecured Subordinated Loan [Member]
Statement [Line Items]
Debt Instrument, Face Amount										$ 1,500,000				$ 1,500,000
Long-term Debt, Current Maturities, Total					$ 500,000
Long-Term Debt, Gross							$ 1,000,000	$ 1,000,000
Skywords Amended Note [Member]
Statement [Line Items]
Debt Instrument, Face Amount	$ 500,000												$ 1,000,000
Debt Instrument, Floor Interest Rate	5%				5%
Prime Rate [Member] | The 2015 Loan Agreement [Member]
Statement [Line Items]
Debt Instrument Reference Rate							7.50%	3.25%
Debt Instrument, Basis Spread on Variable Rate			2%
Prime Rate [Member] | Skywords Note [Member]
Statement [Line Items]
Debt Instrument, Basis Spread on Variable Rate					1%
Prime Rate [Member] | Skywords Note [Member] | Unsecured Subordinated Loan [Member]
Statement [Line Items]
Debt Instrument, Basis Spread on Variable Rate										1%
Prime Rate [Member] | Skywords Note [Member] | Minimum [Member]
Statement [Line Items]
Debt Instrument, Interest Rate During Period					5%
Prime Rate [Member] | Skywords Amended Note [Member]
Statement [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1%
First Foundation Bank [Member] | Revolving Credit Facility [Member]
Statement [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,000,000					$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		4.25%
Line of Credit, Current							$ 1,540,000	$ 0
First Foundation Bank [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]
Statement [Line Items]
Debt Instrument Reference Rate							8%	3.25%
Debt Instrument, Basis Spread on Variable Rate		2%
Related Party 1 [Member] | Revolving Credit Facility [Member]
Statement [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity							$ 1,000,000					$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage							7.50%	5%
Lines of Credit, Related Party, Current							$ 500,000	$ 0

Note 5 - Line of Credit and L_4

Note 5 - Line of Credit and Long-term Debt - Summary of Line of Credit and Long-term Debt (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Less current maturities	$ (5,409,000)	$ (490,000)
Long-term debt, excluding current maturities	1,000,000	4,448,000
Less unamortized debt issuance costs	0	(112,000)
Total long-term debt, net of current maturities and unamortized debt issuance costs	1,000,000	4,336,000
Line of Credit Excluding Related Party [Member]
Statement [Line Items]
Long-term debt	1,540,000	0
Line of Credit, Related Party [Member]
Statement [Line Items]
Long-term debt	500,000	0
Long-term Debt, Excluding Related Party Debt [Member]
Statement [Line Items]
Long-term debt	3,369,000	3,938,000
Unsecured Subordinated Loan [Member]
Statement [Line Items]
Long-term debt	$ 1,000,000	$ 1,000,000

Note 5 - Line of Credit and L_5

Note 5 - Line of Credit and Long-term Debt - Future Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Statement [Line Items]
2024	$ 3,461
2026	1,000
Total principal payments	$ 4,461

Note 6 - Accrued Expenses - Com

Note 6 - Accrued Expenses - Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Bonus and profit sharing	$ 143	$ 488
Wages	215	211
Vacation	393	392
Rent, interest and legal	30	108
Other accrued expenses	320	213
Total accrued expenses	$ 1,101	$ 1,412

Note 7 - Operating Leases (Deta

Note 7 - Operating Leases (Details Textual)	12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Statement [Line Items]
Operating Leases, Expense, Contingent Rentals	$ 0	$ 73,000	$ 50,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	9 years 9 months 18 days	12 years 2 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent	7.30%	7.20%
Operating Lease, Cost	$ 719,000	$ 603,000
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	1,429,000
Operating Lease, Expense	506,000	713,000	616,000
State and Local Jurisdiction [Member]
Statement [Line Items]
Real Estate Tax Expense	$ 37,000	$ 30,000	$ 28,000
Solar Lease for Buildings [Member]
Statement [Line Items]
Leases, Number of Lease Properties	2
Lessee, Operating Lease, Term of Contract (Year)	84 months
Equipment [Member]
Statement [Line Items]
Lessee, Operating Lease, Term of Contract (Year)	48 years
HAWAII1 [Member]
Statement [Line Items]
Leases, Number of Lease Properties	2
HAWAII1 [Member] | Commercial Lease Expiring in 2035 [Member]
Statement [Line Items]
Lessee, Operating Lease, Term of Contract (Year)	40 years
HAWAII1 [Member] | Commercial Lease Expiring in 2037 [Member]
Statement [Line Items]
Lessee, Operating Lease, Term of Contract (Year)	19 years

Note 7 - Operating Leases - Sup

Note 7 - Operating Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Right-of-use assets	$ 6,149	$ 4,720
Accumulated lease amortization	(1,373)	(933)
Total right-of-use assets	4,776	3,787
Current lease liabilities	483	393
Non-current lease liabilities	4,275	3,386
Total lease liabilities	$ 4,758	$ 3,779

Note 7 - Operating Leases - Ope

Note 7 - Operating Leases - Operating Leases Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
2024	$ 810
2025	820
2026	797
2027	798
2028	683
Thereafter	2,760
Total undiscounted lease payments	6,668
Less: present value discount	(1,910)
Total lease liabilities balance	$ 4,758	$ 3,779

Note 8 - Other Commitments an_2

Note 8 - Other Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Purchase Obligation	$ 822,000	$ 1,105,000	$ 1,005,000
Purchase Obligation Agreement, Term (Year)	10 years

Note 9 - Share-based Compensa_3

Note 9 - Share-based Compensation (Details Textual)			12 Months Ended
	Apr. 06, 2023 $ / shares shares	Apr. 03, 2023 shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Aug. 25, 2016 shares	Aug. 28, 2014 shares
Statement [Line Items]
Number of Shareholder Approved Share-based Compensation Plans			2
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			1,104,643
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			1,950,000
Share Price (in dollars per share) | $ / shares			$ 0.88	$ 3.37	$ 3.30
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value | $			$ 0	$ 0	$ 6,000
ShareBased Compensation Arrangement By Share Based Payment Award Weighted Average Grant Date Fair Value Options Granted | $			97,000	80,000	155,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $			67,000	40,000	6,000
Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-Based Payment Arrangement, Expense | $			90,000	63,000	29,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $			$ 124,000	$ 139,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 7 months 6 days	2 years 1 month 6 days
Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Statement [Line Items]
Share-Based Payment Arrangement, Expense | $			$ 158,000	$ 158,000	$ 158,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			64,489	55,438	66,385
Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | Two Board Members [Member]
Statement [Line Items]
Share-Based Payment Arrangement, Expense | $			$ 15,500
Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | Two Board Members [Member] | Subsequent Event [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		17,672
Restricted Stock Units (RSUs) [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			66,423	38,672	28,647
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares			$ 3.13	$ 2.91	$ 2.15
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Statement [Line Items]
Share-Based Payment Arrangement, Expense | $			$ 62,000	$ 123,000	$ 28,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $			$ 122,000	$ 19,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 3 months 18 days	1 year 2 months 12 days
Restricted Stock Units (RSUs) [Member] | Employees [Member] | Subsequent Event [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	7,900
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 0.94
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years
The 2004 Directors Plan [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			0
The 2016 Plan [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			881,437
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			1,300,000			1,300,000
The 2016 Plan [Member] | Maximum [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized for Issuance in Connection with Performance Awards and Stock Awards (in shares)						600,000
2014 Directors Plan [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			223,206
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			650,000				350,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)			300,000

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details) - shares	Mar. 31, 2023	Aug. 25, 2016	Aug. 28, 2014
Statement [Line Items]
Authorized (in shares)	1,950,000
Available (in shares)	1,104,643
Outstanding (in shares)	323,334
The 2016 Plan [Member]
Statement [Line Items]
Authorized (in shares)	1,300,000	1,300,000
Available (in shares)	881,437
Outstanding (in shares)	305,334
2014 Directors Plan [Member]
Statement [Line Items]
Authorized (in shares)	650,000		350,000
Available (in shares)	223,206
Outstanding (in shares)	12,000
The 2004 Directors Plan [Member]
Statement [Line Items]
Available (in shares)	0
Outstanding (in shares)	6,000

Note 9 - Share-based Compensa_5

Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Statement [Line Items]
Outstanding (in shares)	252,500	374,300	318,300
Outstanding, weighted average exercise price (in dollars per share)	$ 3.34	$ 3.64	$ 4.08
Outstanding, weighted average remaining contractual term (Year)	7 years 6 months	6 years 6 months	3 years 10 months 24 days	3 years
Outstanding, aggregate intrinsic value	$ 0	$ 159,650	$ 129,700	$ 0
Granted (in shares)	50,000	50,000	130,000
Granted, weighted average exercise price (in dollars per share)	$ 3.43	$ 2.96	$ 2.35
Exercised (in shares)			(19,000)
Exercised, weighted average exercise price (in dollars per share)			$ 3.59
Forfeited (in shares)		(5,000)	(55,000)
Forfeited, weighted average exercise price (in dollars per share)		$ 5.21	$ 3.13
Expired (in shares)	(49,500)	(166,800)
Expired, weighted average exercise price (in dollars per share)	$ 5.80	$ 3.84
Outstanding (in shares)	253,000	252,500	374,300	318,300
Outstanding, weighted average exercise price (in dollars per share)	$ 2.88	$ 3.34	$ 3.64	$ 4.08
Exercisable (in shares)	111,333
Exercisable, weighted average exercise price (in dollars per share)	$ 2.90
Exercisable, weighted average remaining contractual term (Year)	6 years 7 months 6 days
Exercisable, aggregate intrinsic value	$ 0

Note 9 - Share-based Compensa_6

Note 9 - Share-based Compensation - Summary of Non-vested Options (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Nonvested (in shares)	141,667
Nonvested (in dollars per share)	$ 1.33
Granted (in shares)	50,000	50,000	130,000
Granted (in dollars per share)	$ 1.94
Expired (in shares)	50,000
Expired (in dollars per share)	$ 1.33
Nonvested (in shares)	141,667	141,667
Nonvested (in dollars per share)	$ 1.55	$ 1.33

Note 9 - Share-based Compensa_7

Note 9 - Share-based Compensation - Summary of the Weighted-average Characteristics of Outstanding Stock Options (Details)	12 Months Ended
	Mar. 31, 2023 $ / shares shares
Statement [Line Items]
Outstanding Options Number of Shares (in shares) | shares	253,000
Outstanding Options Remaining Life (Year)	7 years 6 months
Outstanding Options Weighted Average Price (in dollars per share)	$ 2.88
Exercisable Options Number of Shares (in shares) | shares	111,333
Exercisable Options Weighted Average Price (in dollars per share)	$ 2.90
Range 01 [Member]
Statement [Line Items]
Lower Range of Exercise (in dollars per share)	2.11
Upper Range of Exercise (in dollars per share)	$ 2.34
Outstanding Options Number of Shares (in shares) | shares	105,000
Outstanding Options Remaining Life (Year)	7 years 2 months 12 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 2.28
Exercisable Options Number of Shares (in shares) | shares	55,000
Exercisable Options Weighted Average Price (in dollars per share)	$ 2.27
Range 02 [Member]
Statement [Line Items]
Lower Range of Exercise (in dollars per share)	2.35
Upper Range of Exercise (in dollars per share)	$ 2.76
Outstanding Options Number of Shares (in shares) | shares	30,000
Outstanding Options Remaining Life (Year)	7 years 6 months
Outstanding Options Weighted Average Price (in dollars per share)	$ 2.54
Exercisable Options Number of Shares (in shares) | shares	21,666
Exercisable Options Weighted Average Price (in dollars per share)	$ 2.53
Range 03 [Member]
Statement [Line Items]
Lower Range of Exercise (in dollars per share)	2.77
Upper Range of Exercise (in dollars per share)	$ 3.20
Outstanding Options Number of Shares (in shares) | shares	50,000
Outstanding Options Remaining Life (Year)	8 years 1 month 6 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 2.96
Exercisable Options Number of Shares (in shares) | shares	16,667
Exercisable Options Weighted Average Price (in dollars per share)	$ 2.96
Range 04 [Member]
Statement [Line Items]
Lower Range of Exercise (in dollars per share)	3.21
Upper Range of Exercise (in dollars per share)	$ 5.91
Outstanding Options Number of Shares (in shares) | shares	68,000
Outstanding Options Remaining Life (Year)	7 years 3 months 18 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 3.89
Exercisable Options Number of Shares (in shares) | shares	18,000
Exercisable Options Weighted Average Price (in dollars per share)	$ 5.18

Note 9 - Share-based Compensa_8

Note 9 - Share-based Compensation - Summary of Valuation Assumptions Related to Options Granted (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Exercise Price (in dollars per share)	$ 1.94	$ 1.60	$ 1.20
Volatility	57.47%	58.23%	54.44%
Risk Free Rate	3.36%	1.06%	0.40%
Vesting Period (Year)	3 years	3 years	3 years
Forfeiture Rate	19%	0%	0%
Expected Life (Year)	6 years	6 years	6 years 2 months 12 days
Dividend Rate	0%	0%	0%

Note 9 - Share-based Compensa_9

Note 9 - Share-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Nonvested restricted stock units (in shares)	14,465	28,188	12,766
Nonvested restricted stock units, weighted average grant price (in dollars per share)	$ 2.22	$ 2.38	$ 3.98
Granted (in shares)	66,423	38,672	28,647
Granted, weighted average grant price (in dollars per share)	$ 3.13	$ 2.91	$ 2.15
Vested (in shares)	(8,312)	(46,963)	(9,135)
Vested, weighted average grant price (in dollars per share)	$ 2.35	$ 2.85	$ 3.97
Forfeited (in shares)	(2,242)	(5,432)	(4,090)
Forfeited, weighted average grant price (in dollars per share)	$ 2.91	$ 2.51	$ 2.21
Nonvested restricted stock units (in shares)	70,334	14,465	28,188
Nonvested restricted stock units, weighted average grant price (in dollars per share)	$ 3.04	$ 2.22	$ 2.38

Note 10 - Common and Preferre_2

Note 10 - Common and Preferred Stock (Details Textual) - shares	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Shares Authorized (in shares)	60,000,000
Common Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Preferred Stock, Shares Authorized (in shares)	10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)	0	0

Note 11 - Earnings (Loss) Per_3

Note 11 - Earnings (Loss) Per Share (Details Textual)	12 Months Ended
	Mar. 31, 2023 shares
Common Stock Options and Restricted Stock Units [Member]
Statement [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	3,000

Note 11 - Earnings (Loss) Per_4

Note 11 - Earnings (Loss) Per Share - Summary of Reconciliations Between the Numerator and the Denominator of the Basic and Diluted Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Net (loss) income	$ (3,440)	$ 2,154	$ 920
Basic (in shares)	6,244	6,157	6,070
Basic (in dollars per share)	$ (0.55)	$ 0.35	$ 0.15
Shares outstanding - basic (in shares)	6,244	6,157	6,070
Earnings per share - basic (in dollars per share)	$ (0.55)	$ 0.35	$ 0.15
Effective dilutive securities—Common stock options and restricted stock units		$ 0	$ 0
Effective dilutive securities—Common stock options and restricted stock units (in shares)		11	8
Net income - diluted		$ 2,154	$ 920
Shares outstanding - diluted (in shares)	6,244	6,168	6,079
Diluted income per share (in dollars per share)	$ (0.55)	$ 0.35	$ 0.15
Diluted (in dollars per share)	$ (0.55)	$ 0.35	$ 0.15

Note 12 - Profit Sharing and _2

Note 12 - Profit Sharing and 401k Plan (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Profit Sharing Defined Contribution Plan [Member]
Statement [Line Items]
Defined Contribution Plan, Cost	$ 0	$ 121,000	$ 25,000
Defined Contribution 401K Plan [Member]
Statement [Line Items]
Defined Contribution Plan, Cost	$ 138,000	$ 135,000	$ 141,000
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2%

Note 13 - Product Line and Ge_3

Note 13 - Product Line and Geographic Information (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Cost of Goods and Services Sold	$ 15,919,000	$ 22,402,000	$ 21,228,000
Contract Extraction [Member]
Statement [Line Items]
Cost of Goods and Services Sold	$ 441,000	$ 439,000	$ 337,000

Note 13 - Product Line and Ge_4

Note 13 - Product Line and Geographic Information - Net Sales by Product Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Total net sales	$ 23,178	$ 35,968	$ 32,345
Packaged Astaxanthin [Member]
Statement [Line Items]
Total net sales	12,227	14,931	14,512
Packaged Spirulina [Member]
Statement [Line Items]
Total net sales	4,814	7,604	7,616
Packaged Products [Member]
Statement [Line Items]
Total net sales	17,041	22,535	22,128
Bulk Astaxanthin [Member]
Statement [Line Items]
Total net sales	1,982	2,447	2,279
Bulk Spirulina [Member]
Statement [Line Items]
Total net sales	3,541	10,386	7,119
Bulk Products [Member]
Statement [Line Items]
Total net sales	5,523	12,833	9,398
Contract Extraction and R&D Services [Member]
Statement [Line Items]
Total net sales	$ 614	$ 600	$ 819

Note 13 - Product Line and Ge_5

Note 13 - Product Line and Geographic Information - Sales by Geographic Region (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Net sales		$ 23,178	$ 35,968	$ 32,345
Geographic Concentration Risk [Member]
Statement [Line Items]
Net sales	[1]	$ 23,178	$ 35,968	$ 32,345
Net sales, percent	[1]	100%	100%	100%
Geographic Concentration Risk [Member] | UNITED STATES
Statement [Line Items]
Net sales	[1]	$ 17,031	$ 24,468	$ 21,474
Net sales, percent	[1]	73%	68%	66%
Geographic Concentration Risk [Member] | Asia Pacific [Member]
Statement [Line Items]
Net sales	[1]	$ 2,164	$ 7,102	$ 5,827
Net sales, percent	[1]	9%	20%	18%
Geographic Concentration Risk [Member] | Europe [Member]
Statement [Line Items]
Net sales	[1]	$ 2,440	$ 3,183	$ 3,416
Net sales, percent	[1]	11%	9%	11%
Geographic Concentration Risk [Member] | Other Countries [Member]
Statement [Line Items]
Net sales	[1]	$ 1,543	$ 1,215	$ 1,628
Net sales, percent	[1]	7%	3%	5%
[1]Net sales are attributed to countries based on location of customer.

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%	21%
Operating Loss Carryforwards	$ 14,053,000
Domestic Tax Authority [Member]
Statement [Line Items]
Operating Loss Carryforwards	$ 14,053,000
Operating Loss Carryforwards, Expiration Period (Year)	20 years
Domestic Tax Authority [Member] | Prior To 2018 Tax Year [Member]
Statement [Line Items]
Operating Loss Carryforwards Subject to Expiration	$ 7,203,000
Operating Loss Carryforwards Not Subject to Expiration	6,850,000
State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	11,150,000
State and Local Jurisdiction [Member] | Other States [Member]
Statement [Line Items]
Operating Loss Carryforwards	290,000
State and Local Jurisdiction [Member] | Carryforwards Expire March 31, 2039 through 2040 [Member] | California Franchise Tax Board [Member]
Statement [Line Items]
Operating Loss Carryforwards Subject to Expiration	2,946,000
State and Local Jurisdiction [Member] | Carryforwards Expire March 31, 2030 through 2040 [Member] | State of Hawaii Department of Taxation [Member]
Statement [Line Items]
Operating Loss Carryforwards Subject to Expiration	$ 7,914,000

Note 14 - Income Taxes - Compon

Note 14 - Income Taxes - Components of Income Tax Benefit (Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Federal	$ 0	$ 0	$ 0
State	(18)	(28)	(3)
Total current (expense) benefit	(18)	(28)	(3)
Federal	0	0	0
State	0	0	0
Total deferred expense	0	0	0
Income tax expense	$ (18)	$ (28)	$ (3)

Note 14 - Income Taxes - Reconc

Note 14 - Income Taxes - Reconciliation of the Amount of Income Taxes Computed at the Federal Statutory Rate to the Amount Reflected in Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Tax provision at federal statutory income tax rate	$ 952	$ (591)	$ (263)
Stock-based compensation	(23)	(16)	(11)
Decrease (increase) in valuation allowance	(518)	557	(17)
State and local income taxes, net of federal tax benefit	(12)	(2)	1
Expired losses	(380)	0	0
Deferred tax true-up	(24)	34	27
CARES Act, PPP Loan Forgiveness	0	0	298
Other, net	(13)	(10)	(38)
Income tax expense	$ (18)	$ (28)	$ (3)

Note 14 - Income Taxes - Effect

Note 14 - Income Taxes - Effects of Temporary Differences Related to Various Assets, Liabilities and Carry Forwards That Give Rise to Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Net operating loss carry forwards	$ 3,570	$ 3,140
Inventory	50	175
Compensation accrual	177	251
Tax credit carry forwards	28	28
Interest limitation	108	0
Operating lease right-of-use assets	1,323	1,025
Section 174 Costs	118	0
Other	26	27
Gross deferred tax assets	5,400	4,646
Less valuation allowance	(2,990)	(2,473)
Net deferred tax assets	2,410	2,173
Operating lease obligations	(1,328)	(1,027)
Depreciation and amortization	(1,082)	(1,146)
Net deferred tax liabilities	(2,410)	(2,173)
Net deferred tax assets (liabilities)	$ 0	$ 0

Note 14 - Income Taxes - Net Op

Note 14 - Income Taxes - Net Operating Loss Carry Forwards and Tax Credit Carry Forwards Available to Offset Future Federal Income Tax (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Statement [Line Items]
Operating Loss Carryforwards	$ 14,053
Research Tax Credit Carryforward [Member]
Statement [Line Items]
Research and Experimentation Tax Credits	28
State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	11,150
Expiration Tax Year 2025 [Member]
Statement [Line Items]
Operating Loss Carryforwards	0
Expiration Tax Year 2025 [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Research and Experimentation Tax Credits	8
Expiration Tax Year 2025 [Member] | State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	0
Expiration Tax Year 2026 [Member]
Statement [Line Items]
Operating Loss Carryforwards	159
Expiration Tax Year 2026 [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Research and Experimentation Tax Credits	2
Expiration Tax Year 2026 [Member] | State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	0
Expiration Tax Year 2027 [Member]
Statement [Line Items]
Operating Loss Carryforwards	2,665
Expiration Tax Year 2027 [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Research and Experimentation Tax Credits	0
Expiration Tax Year 2027 [Member] | State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	0
Expiration Tax Year After 2027 [Member]
Statement [Line Items]
Operating Loss Carryforwards	4,379
Expiration Tax Year After 2027 [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Research and Experimentation Tax Credits	18
Expiration Tax Year After 2027 [Member] | State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	11,150
Indefinite [Member]
Statement [Line Items]
Operating Loss Carryforwards	6,850
Indefinite [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Research and Experimentation Tax Credits	0
Indefinite [Member] | State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards	$ 0

Note 14 - Income Taxes - Open T

Note 14 - Income Taxes - Open Tax Years and Jurisdictions That the Company Used in Its Evaluation of Tax Positions (Details)	12 Months Ended
	Mar. 31, 2023
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member]
Statement [Line Items]
Open tax year
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Latest Tax Year [Member]
Statement [Line Items]
Open tax year	2023
State and Local Jurisdiction [Member] | Hawaii Department of Taxation [Member] | Earliest Tax Year [Member]
Statement [Line Items]
Open tax year
State and Local Jurisdiction [Member] | Hawaii Department of Taxation [Member] | Latest Tax Year [Member]
Statement [Line Items]
Open tax year	2023
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | Earliest Tax Year [Member]
Statement [Line Items]
Open tax year
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | Latest Tax Year [Member]
Statement [Line Items]
Open tax year	2023

Note 15 - Related Party Trans_2

Note 15 - Related Party Transactions and Balances (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
	Apr. 12, 2021	Apr. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Dec. 14, 2022	Apr. 30, 2019
Statement [Line Items]
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 408,000	$ 342,000	$ 446,000
Long-Term Debt, Total			4,461,000
Lines of Credit, Related Party, Current			500,000	0
Revolving Credit Facility [Member] | Related Party 1 [Member]
Statement [Line Items]
Lines of Credit, Related Party, Current			$ 500,000	$ 0
Debt Instrument, Interest Rate, Stated Percentage			7.50%	5%
Conversion of Skywords Note Into Revolving Loans [Member]
Statement [Line Items]
Debt Conversion, Original Debt, Amount	$ 500,000
Skywords Note [Member]
Statement [Line Items]
Repayments of Long-term Debt, Total	500,000	$ 500,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	1,900	$ 1,900
Skywords Note [Member] | Prime Rate [Member]
Statement [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1%
Skywords Note [Member] | Unsecured Subordinated Loan [Member]
Statement [Line Items]
Debt Instrument, Face Amount						$ 1,500,000		$ 1,500,000
Long-Term Debt, Total			$ 1,000,000
Skywords Note [Member] | Unsecured Subordinated Loan [Member] | Prime Rate [Member]
Statement [Line Items]
Debt Instrument, Basis Spread on Variable Rate						1%
Skywords Amended Note [Member]
Statement [Line Items]
Debt Instrument, Face Amount	$ 500,000						$ 1,000,000
Debt Instrument, Term (Year)	3 years
Debt Instrument, Floor Interest Rate	5%	5%
Skywords Amended Note [Member] | Prime Rate [Member]
Statement [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1%

Schedule II - Valuation and Q_3

Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Allowance, Credit Loss [Member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Balance at Beginning of Year	$ 67	$ 32	$ 13
Additions Charged to Costs and Expense	64	40	46
Additions Charged to Other Accounts	0	0	0
Deductions	67	5	27
Balance at End of Year	$ 64	$ 67	$ 32